FDA approves 1st cell-based seasonal flu vaccine
from American Society of Health-System Pharmacists
The FDA recently announced the licensing of the nation's first seasonal influenza virus vaccine produced in a cell culture system instead of the traditional egg-based technology. Flucelvax, made by Novartis Vaccines, is an inactivated vaccine derived from virus propagated in a continuous cell line of canine kidney cell origin.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063